全文获取类型
收费全文 | 3252篇 |
免费 | 163篇 |
国内免费 | 104篇 |
专业分类
耳鼻咽喉 | 22篇 |
儿科学 | 207篇 |
妇产科学 | 113篇 |
基础医学 | 392篇 |
口腔科学 | 83篇 |
临床医学 | 315篇 |
内科学 | 726篇 |
皮肤病学 | 121篇 |
神经病学 | 121篇 |
特种医学 | 430篇 |
外科学 | 286篇 |
综合类 | 108篇 |
预防医学 | 143篇 |
眼科学 | 43篇 |
药学 | 215篇 |
2篇 | |
中国医学 | 17篇 |
肿瘤学 | 175篇 |
出版年
2021年 | 26篇 |
2020年 | 27篇 |
2019年 | 28篇 |
2018年 | 61篇 |
2017年 | 38篇 |
2016年 | 51篇 |
2015年 | 71篇 |
2014年 | 92篇 |
2013年 | 111篇 |
2012年 | 98篇 |
2011年 | 114篇 |
2010年 | 133篇 |
2009年 | 115篇 |
2008年 | 87篇 |
2007年 | 163篇 |
2006年 | 107篇 |
2005年 | 121篇 |
2004年 | 81篇 |
2003年 | 92篇 |
2002年 | 79篇 |
2001年 | 77篇 |
2000年 | 69篇 |
1999年 | 61篇 |
1998年 | 142篇 |
1997年 | 164篇 |
1996年 | 136篇 |
1995年 | 112篇 |
1994年 | 117篇 |
1993年 | 98篇 |
1992年 | 40篇 |
1991年 | 49篇 |
1990年 | 49篇 |
1989年 | 65篇 |
1988年 | 64篇 |
1987年 | 51篇 |
1986年 | 71篇 |
1985年 | 53篇 |
1984年 | 29篇 |
1983年 | 22篇 |
1982年 | 25篇 |
1981年 | 31篇 |
1980年 | 27篇 |
1979年 | 20篇 |
1978年 | 21篇 |
1977年 | 25篇 |
1976年 | 33篇 |
1975年 | 24篇 |
1972年 | 22篇 |
1971年 | 16篇 |
1969年 | 18篇 |
排序方式: 共有3519条查询结果,搜索用时 0 毫秒
61.
Michael Moore Beth Stuart Samuel Coenen Chris C Butler Herman Goossens Theo JM Verheij Paul Little 《The British journal of general practice》2014,64(619):e75-e80
Background
Antibiotics are of limited overall clinical benefit for uncomplicated lower respiratory tract infection (LRTI) but there is uncertainty about their effectiveness for patients with features associated with higher levels of antibiotic prescribing.Aim
To estimate the benefits and harms of antibiotics for acute LRTI among those producing coloured sputum, smokers, those with fever or prior comorbidities, and longer duration of prior illness.Design and setting
Secondary analysis of a randomised controlled trial of antibiotic placebo for acute LRTI in primary care.Method
Two thousand and sixty-one adults with acute LRTI, where pneumonia was not suspected clinically, were given amoxicillin or matching placebo. The duration of symptoms, rated moderately bad or worse (primary outcome), symptom severity on days 2–4 (0–6 scale), and the development of new or worsening symptoms were analysed in pre-specified subgroups of interest. Evidence of differential treatment effectiveness was assessed in prespecified subgroups by interaction terms.Results
No subgroups were identified that were significantly more likely to benefit from antibiotics in terms of symptom duration or the development of new or worsening symptoms. Those with a history of significant comorbidities experienced a significantly greater reduction in symptom severity between days 2 and 4 (interaction term −0.28, P = 0.003; estimated effect of antibiotics among those with a past history −0.28 [95% confidence interval = −0.44 to −0.11], P = 0.001), equivalent to three people in 10 rating symptoms as a slight rather than a moderately bad problem. For subgroups not specified in advance antibiotics provided a modest reduction in symptom severity for non-smokers and for those with short prior illness duration (<7 days), and a modest reduction in symptom duration for those with short prior illness duration.Conclusion
There is no clear evidence of clinically meaningful benefit from antibiotics in the studied high-risk groups of patients presenting in general practice with uncomplicated LRTIs where prescribing is highest. Any possible benefit must be balanced against the side-effects and longer-term effects on antibiotic resistance. 相似文献62.
63.
64.
Janiszewska H Bak A Pilarska M Heise M Junkiert-Czarnecka A Kuliszkiewicz-Janus M Całbecka M Jaźwiec B Wołowiec D Kuliczkowski K Haus O 《Haematologica》2012,97(3):366-370
Germline mutations of the CHEK2 gene have been reported in some myeloid and lymphoid malignancies, but their impact on development of essential thrombocythemia has not been studied. In 16 out of 106 (15.1%) consecutive patients, newly diagnosed with essential thrombocythemia, we found one of four analyzed CHEK2 mutations: I157T, 1100delC, IVS2+1G>A or del5395. They were associated with the increased risk of disease (OR=3.8; P=0.002). The median age at ET diagnosis among CHEK2+/JAK2V617F+ patients was seven years lower than that among CHEK2-/JAK2V617F+ (52 vs. 59 years; P=0.04), whereas there was no difference in the medians of hematologic parameters between these groups. The results obtained suggest that CHEK2 mutations could potentially contribute to the susceptibility to essential thrombocythemia. The germline inactivation of CHEK2, as it seems, has no direct impact on the development of disease, but it could cause disruption of cell cycle checkpoints and initiate or support the cancerogenic process of essential thrombocythemia at a younger age. 相似文献
65.
66.
67.
Michał Bogusiewicz Marta Monist Krzysztof Gałczyński Magdalena Woźniak Andrzej P. Wieczorek Tomasz Rechberger 《World journal of urology》2014,32(6):1605-1611
Purpose
To investigate whether the position of the tape under the urethra may influence ‘outside-in’ transobturator sling (TOT) outcome.Methods
The study comprised 141 women who underwent TOT for clinically and urodynamically proved stress urinary incontinence. The postoperative ultrasound examination with an endovaginal biplane probe was performed before discharging the patients from hospital. The measurements obtained described the position of the tape relative to the urethra and pubic symphysis, as well as anatomical relationships in the anterior compartment.Results
Ninety-six (68.1 %) patients were cured, 27 (19.1 %) significantly improved, and in 18 cases (12.7 %), the surgery failed. The tape position under the midurethra (40–70th percentile of the urethral length) or distal urethra (>70th percentile) coincided with better results (cure rate 67.1 and 82.4 %, respectively) than the location in the proximity of the bladder neck (<40th percentile) (21.4 % cured, p = 0.0015 and p < 0.001, respectively). However, the risk of failure was the lowest when the tape was located under the distal urethra. Other ultrasonographic findings were not related to treatment results.Conclusions
The highest failure rate for ‘outside-in’ TOT is associated with the location of the tape under the proximal third of the urethra. Both the middle and distal sections of the urethra may be regarded as targets for transobturator tape placement. 相似文献68.
Jen-Chung Ko Hsien-Chun Chiu Jhan-Jhang Syu Yi-Jun Jian Chien-Yu Chen Yun-Ting Jian Yi-Jhen Huang Ting-Yu Wo Yun-Wei Lin 《Biochemical pharmacology》2014
Tamoxifen is a triphenylethylene nonsteroidal estrogen receptor (ER) antagonist used worldwide as an adjuvant hormone therapeutic agent in the treatment of breast cancer. However, the molecular mechanism of tamoxifen-induced cytotoxicity in non-small cell lung cancer (NSCLC) cells has not been identified. Thymidine phosphorylase (TP) is an enzyme of the pyrimidine salvage pathway which is upregulated in cancers. In this study, tamoxifen treatment inhibited cell survival in two NSCLC cells, H520 and H1975. Treatment with tamoxifen decreased TP mRNA and protein levels through AKT inactivation. Furthermore, expression of constitutively active AKT (AKT-CA) vectors significantly rescued the decreased TP protein and mRNA levels in tamoxifen-treated NSCLC cells. In contrast, combination treatment with PI3K inhibitors (LY294002 or wortmannin) and tamoxifen further decreased the TP expression and cell viability of NSCLC cells. Knocking down TP expression by transfection with small interfering RNA of TP enhanced the cytotoxicity and cell growth inhibition of tamoxifen. Erlotinib (Tarceva, OSI-774), an orally available small molecular inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, is approved for clinical treatment of NSCLC. Compared to a single agent alone, tamoxifen combined with erlotinib resulted in cytotoxicity and cell growth inhibition synergistically in NSCLC cells, accompanied with reduced activation of phospho-AKT and phospho-ERK1/2, and reduced TP protein levels. These findings may have implications for the rational design of future drug regimens incorporating tamoxifen and erlotinib for the treatment of NSCLC. 相似文献
69.
Maria Kopeć Zdzisława S̀wierczyńska Jacek Pazdur Stanisław Luft Maria Płachecka Maria Dabska Danuta Glińska Genowefa Woźniczko-Orłowska 《The American journal of medicine》1974,56(3):381-385
Monoclonal gammopathy of IgG3 kappa type is described in a young man with diffuse lymphoid infiltration of the stomach duodenum and intestines. 相似文献
70.
Cairo MS; Christensen R; Sender LS; Ellis R; Rosenthal J; van de Ven C; Worcester C; Agosti JM 《Blood》1995,86(7):2509-2515
Neonates, especially those of very low birthweight (VLBW), have an increased risk of nosocomial infections secondary to deficiencies in development. We previously demonstrated that granulocyte-macrophage colony-stimulating factor (GM-CSF) production and mRNA expression from stimulated neonatal mononuclear cells are significantly less than that from adult cells. Recombinant murine GM-CSF administration to neonatal rats has resulted in neutrophilia, increased neutrophil production, and increased survival of pups during experimental Staphylococcus aureus sepsis. In the present study, we sought to determine the safety and biologic response of recombinant human (rhu) GM-CSF in VLBW neonates. Twenty VLBW neonates (500 to 1,500 g), aged < 72 hours, were randomized to receive either placebo (n = 5) or rhuGM-CSF at 5.0 micrograms/kg once per day (n = 5), 5.0 micrograms/kg twice per day (n = 5), or 10 micrograms/kg once per day (n = 5) given via 2-hour intravenous infusion for 7 days. Complete blood counts, differential, and platelet counts were obtained, and tibial bone marrow aspirate was performed on day 8. Neutrophil C3bi receptor expression was measured at 0 and 24 hours. GM-CSF levels were measured by a sandwich enzyme-linked immunosorbent assay at 2, 4, 6, 12, and 24 hours after the first dose of rhuGM-CSF. At all doses, rhuGM-CSF was well tolerated, and there was no evidence of grade III or IV toxicity. Within 48 hours of administration, there was a significant increase in the circulating absolute neutrophil count (ANC) at 5.0 micrograms/kg twice per day and 10.0 micrograms/kg once per day, which continued for at least 24 hours after discontinuation of rhuGM-CSF. When the ANC was normalized for each patient's first ANC, there was a significant increase in the ANC on days 6 and 7 at each dose level. By day 7, all tested doses of rhuGM- CSF resulted in an increase in the absolute monocyte count (AMC) compared with placebo-treated neonates. In those receiving rhuGM-CSF 5.0 micrograms/kg twice per day, there was additionally a significant increase in the day 7 and 8 platelet count. Tibial bone marrow aspirates demonstrated a significant increase in the bone marrow neutrophil storage pool (BM NSP) at 5.0 micrograms/kg twice per day and 10.0 micrograms/kg once per day. Neutrophil C3bi receptor expression was significantly increased 24 hours after the first dose of rhuGM-CSF at 5.0 micrograms/kg once per day. The elimination half-life (T1/2) of rhuGM-CSF was 1.4 +/- 0.8 to 3.9 +/- 2.8 hours.(ABSTRACT TRUNCATED AT 400 WORDS) 相似文献